Prostate specific antigen (PSA) - Conjugated

Included in meta analysis

Reference

Reference
Carobene A, Guerra E, Locatelli M, Cucchiara V, Briganti A, Aarsand AK et al, 2018, Clin Chim Acta, 486, 185-91 , Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer

Scoring

Total Score

A1,2,3,4,5,6,7,8,9,10,11,12,13,14

Parameter Score
1. Scale A
2. Study Population A
3. Samples A
4. Measurand A
5. Pre-Analytical A
6. Replicate Analysis A
7. Steady State A
8. Outlier Analysis A
9. Normality A
10. Variance Homogeneity A
11. ANOVA A
12. CI A
13. No of Results A
14. Concentrations A
15. Total Score A1,2,3,4,5,6,7,8,9,10,11,12,13,14
Comment

Item Details

Parameter Score
Matrix Serum
Measurand Prostate specific antigen (PSA) - Conjugated
Unit ug / ug
Overall Analytical Principle Method Immunoassay; Other
Number of Subjects 37
Number of Subjects included in BV estimation 34
Ethinicity Caucasian
Age Mean / Median 35.0
Age Min 22.0
Age Max 59.0
Age SD
Number of Males 37
Number of Females 0
State of Well Being
Healthy (excl pregnant)
Diseases
Study Duration Length 10
Study Duration Units Week
Sampling Intervals, e.g. X sample(s) per Interval Unit 1
Interval Units Week
Sampling Times Start Time: 08.30
End Time: 10.30
Number of Samples 10
Average Number of Samples Used for BV Estimation 9.03
Average Number of Replicates 1.91
Estimates of CVi 8.8
Calculated Confidence Intervals of CVi Lower: 8.00, Upper: 9.72
Estimates of CVg 57.7
Calculated Confidence Intervals of CVg Lower: 46.63, Upper: 75.65
Analytical CV 4.7
Calculated Confidence Intervals of Analytical CV Lower: 4.34, Upper: 5.13
Measurand Mean 0.53
Measurand Min
Measurand Max
Measurand SD

Coding